Halozyme Therapeutics (HALO) PT Lowered to $20 at Citi on 'Very Poor PEGPH20 Pancreatic Cancer Data'
-
Pre-Open Stock Movers 01/06: (ETRM) (OGXI) (STML) Higher; (RT) (GIII) (REGN) Lower (more...)
-
Citi Downgrades Halozyme Therapeutics (HALO) to Neutral
-
Notable Analyst Rating Changes 11/3: (LC) (ITRI) (FINL) Upgraded; (SRCL) (FIT) (SKX) Downgraded
-
Pre-Open Stock Movers 05/10: (CCXI) (ALXA) (GPRO) Higher; (NLNK) (SCTY) (MNKD) Lower (more...)
-
After-Hours Stock Movers 05/09: (STMP) (OPK) (HALO) Higher; (NLNK) (GPS) (BLOX) (RAX) Lower (more...)
-
Citi Starts Halozyme Therapeutics (HALO) at Buy
-
Market Wrap: Intel, Altera Make it Official; Personal Spending Flatlines in April; ASCO Presentations in Focus
-
Notable Analyst Rating Changes 07/11: (LOGM) (QLGC) (ECOM) Upgraded; (FINL) (PG) (EAT) Downgraded
-
Notable Analyst Rating Changes 04/15: (CHS) (C) (YHOO) Upgraded; (WMT) (PETM) (MDT) Downgraded
-
Citi Starts Halozyme Therapeutics (HALO) at Buy
-
Halozyme Therapeutics (HALO) Prices 7.7M Offering at $13/Share
-
Pre-Open Movers 9/21: (HALO) (VPHM) (TIBX) Higher; (PEIX) (ASTX) (VVUS) Lower (more...)
-
Trading Radar for 03/09: Carnival (CCL), Ann, Inc. (ANN), Delcath (DCTH), Citi Trends (CTRN) Report
-
Morning Movers 5/7: SXE, NCT, NANO, CDII, COGO, WNC Higher; TRMA, INAP, CAMP, GXDX, POWR, HLIT, HANS Lower